A case-control study of multiple system atrophy in Korean patients

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1953-1959

  Seo, Joo Hyun ^a   Yong, Seok Woo ^b   Song, Sook K ^a   Lee, Ji E ^a   Sohn, Young H ^a   Lee, Phil Hyu ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Epidemiology; Multiple system atrophy; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGRICULTURAL WORKER; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARMY; ARTICLE; CASE CONTROL STUDY; CLINICAL EVALUATION; COFFEE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DRUG USE; EATING HABIT; EDUCATIONAL STATUS; ENVIRONMENTAL EXPOSURE; FEMALE; FISH; FOOD INTAKE; GENDER; GROUPS BY AGE; HUMAN; INTERVIEW; KOREA; MAJOR CLINICAL STUDY; MALE; MEAT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OCCUPATION; POULTRY; PRIORITY JOURNAL; RESIDENTIAL AREA; RISK ASSESSMENT; RISK REDUCTION; RURAL AREA; SHY DRAGER SYNDROME; SMOKING; STRUCTURED QUESTIONNAIRE; TEA; VITAMIN SUPPLEMENTATION; WESTERN HEMISPHERE;

AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DIET; HUMANS; MULTIPLE SYSTEM ATROPHY; ODDS RATIO; PREVALENCE; QUESTIONNAIRES; REGRESSION ANALYSIS; REPUBLIC OF KOREA; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 77956828791     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23185     Document Type: Article

References (40)

1. Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
2. Wenning GK, Stefanova N, Jellinger KA, et al. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008;64:239-246.
3. Wullner U, Schmitt I, Kammal M, et al. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 2009;80:449-450.
4. Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. Arch Neurol 2007;64:545-551.
5. Soma H, Yabe I, Takei A, et al. Heredity in multiple system atrophy. J Neurol Sci 2006;240:107-110.
6. Nee LE, Gomez MR, Dambrosia J, et al. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1991;1:9-13.
7. Vanacore N, Bonifati V, Fabbrini G, et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 2001;22:97-99.
8. Vanacore N, Bonifati V, Fabbrini G, et al. Case-control study of multiple system atrophy. Mov Disord 2005;20:158-163. (Pubitemid 40361118)
9. Vidal JS, Vidailhet M, Elbaz A, et al. Risk factors of multiple system atrophy: a case-control study in French patients. Mov Disord 2008;23:797-803.
10. Yabe I, Soma H, Takei A, et al. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci 2006;249:115-121. (Pubitemid 44665914)
11. Lee PH, Lim TS, Shin HW, et al. Serum cholesterol levels and the risk of multiple system atrophy: a case-control study. Mov Disord 2009;24:752-758.
12. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74:189-192.
13. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 2002;23:136-139. (Pubitemid 34185415)
14. Yuan X, Koh HL, Chui WK. The analysis of heavy metals in Chinese herbal medicine by flow injection-mercury hydride system and graphite furnace atomic absorption spectrometry. Phytochem Anal 2009;20:293-297.
15. Cooper K, Noller B, Connell D, et al. Public health risks from heavy metals and metalloids present in traditional Chinese medicines. J Toxicol Environ Health A 2007;70:1694-1699.
16. Wang XP, Yang RM. Movement disorders possibly induced by traditional chinese herbs. Eur Neurol 2003;50:153-159.
17. Markowitz SB, Nunez CM, Klitzman S, et al. Lead poisoning due to hai ge fen. The porphyrin content of individual erythrocytes. JAMA 1994;271:932-934.
18. Yim OK, Han EJ, Chung JY, et al. The Monitoring of some heavy metals in oriental herbal medicines and their intake rates. Anal Sci Technol 2009;22:128-135.
19. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12:1161-1208.
20. Yamin G, Glaser CB, Uversky VN, et al. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem 2003;278:27630-27635.
21. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann N Y Acad Sci 1992;669:7-20.
22. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265-1272. (Pubitemid 30174045)
23. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61:82-88.
24. de Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 1997;54:762-765.
25. Zhang SM, Hernan MA, Chen H, et al. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002;59:1161-1169.
26. Stefanova N, Reindl M, Neumann M, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005;166:869-876.
27. Ubhi K, Lee PH, Adame A, et al. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alphasynuclein in a transgenic mouse model of multiple system atrophy. J Neurosci Res 2009;87:2728-2739.
28. Chrysostome V, Tison F, Yekhlef F, et al. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 2004;23:201-208. (Pubitemid 38980446)
29. Logroscino G, Marder K, Cote L, et al. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol 1996;39:89-94.
30. de Lau LM, Koudstaal PJ, Hofman A, et al. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006;164:998-1002. (Pubitemid 44729842)
31. Simon KC, Chen H, Schwarzschild M, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69:1688-1695. (Pubitemid 350287125)
32. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 2007;22:377-381.
33. Hu G, Antikainen R, Jousilahti P, et al. Total cholesterol and the risk of Parkinson disease. Neurology 2008;70:1972-1979.
34. Davidson WS, Jonas A, Clayton DF, et al. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998;273:9443-9449.
35. Kaikkonen J, Nyyssonen K, Tuomainen TP, et al. Determinants of plasma coenzyme Q10 in humans. FEBS Lett 1999;443:163-166. (Pubitemid 29078624)
36. Hernan MA, Takkouche B, Caamano-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
37. Hu G, Bidel S, Jousilahti P, et al. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 2007;22:2242-2248.
38. Vanacore N, Bonifati V, Fabbrini G, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 2000;54:114-119.
39. Reitz C, den Heijer T, van Duijn C, et al. Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology 2007;69:998-1005. (Pubitemid 47366053)
40. Dallongeville J, Marecaux N, Fruchart JC, et al. Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J Nutr 1998;128:1450-1457.